Cargando…

Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction

This study aims to construct a Macrophage-Related Gene Prognostic Index (MRGPI) for glioblastoma (GBM) and explore the underlying molecular, metabolic, and immunological features. Based on the GBM dataset from The Cancer Genome Atlas (n = 156), 13 macrophage-related hub genes were identified by weig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Hang, Liu, Zhihui, Wang, Fang, Sun, Haogeng, Wang, Nan, Liu, Yi, Hu, Shaoshan, You, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513135/
https://www.ncbi.nlm.nih.gov/pubmed/36177003
http://dx.doi.org/10.3389/fimmu.2022.941556
_version_ 1784797988963483648
author Ji, Hang
Liu, Zhihui
Wang, Fang
Sun, Haogeng
Wang, Nan
Liu, Yi
Hu, Shaoshan
You, Chao
author_facet Ji, Hang
Liu, Zhihui
Wang, Fang
Sun, Haogeng
Wang, Nan
Liu, Yi
Hu, Shaoshan
You, Chao
author_sort Ji, Hang
collection PubMed
description This study aims to construct a Macrophage-Related Gene Prognostic Index (MRGPI) for glioblastoma (GBM) and explore the underlying molecular, metabolic, and immunological features. Based on the GBM dataset from The Cancer Genome Atlas (n = 156), 13 macrophage-related hub genes were identified by weighted gene co-expression network (WGCNA) analysis. 5 prognostic genes screened by Kaplan-Meire (K-M) analysis and Cox regression model were used to construct the MRGPI, including GPR84, NCF2, HK3, LILRB2, and CCL18. Multivariate Cox regression analysis found that the MRGPI was an independent risk factor (HR = 2.81, CI95: 1.13-6.98, p = 0.026), leading to an unfavorable outcome for the MRGPI-high group, which was further validated by 4 validation GBM cohorts (n = 728). Thereafter, the molecular, metabolic, and immune features and the clinical implications of the MRGPI-based groups were comprehensively characterized. Gene set enrichment analysis (GSEA) found that immune-related pathways, including inflammatory and adaptive immune response, and activated eicosanoid metabolic pathways were enriched in the MRGPI-high group. Besides, genes constituting the MRGPI was primarily expressed by monocytes and macrophages at single-cell scope and was associated with the alternative activation of macrophages. Moreover, correlation analysis and receiver operating characteristic (ROC) curves revealed the relevance between the MRGPI with the expression of immune checkpoints and T cell dysfunction. Thus, the responsiveness of samples in the MRGPI-high group to immune checkpoint inhibitors (ICI) was detected by algorithms, including Tumor Immune Dysfunction and Exclusion (TIDE) and Submap. In contrast, the MRGPI-low group had favorable outcome, was less immune active and insensitive to ICI. Together, we have developed a promising biomarker to classify the prognosis, metabolic and immune features for GBM, and provide references for facilitating the personalized application of ICI in GBM.
format Online
Article
Text
id pubmed-9513135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95131352022-09-28 Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction Ji, Hang Liu, Zhihui Wang, Fang Sun, Haogeng Wang, Nan Liu, Yi Hu, Shaoshan You, Chao Front Immunol Immunology This study aims to construct a Macrophage-Related Gene Prognostic Index (MRGPI) for glioblastoma (GBM) and explore the underlying molecular, metabolic, and immunological features. Based on the GBM dataset from The Cancer Genome Atlas (n = 156), 13 macrophage-related hub genes were identified by weighted gene co-expression network (WGCNA) analysis. 5 prognostic genes screened by Kaplan-Meire (K-M) analysis and Cox regression model were used to construct the MRGPI, including GPR84, NCF2, HK3, LILRB2, and CCL18. Multivariate Cox regression analysis found that the MRGPI was an independent risk factor (HR = 2.81, CI95: 1.13-6.98, p = 0.026), leading to an unfavorable outcome for the MRGPI-high group, which was further validated by 4 validation GBM cohorts (n = 728). Thereafter, the molecular, metabolic, and immune features and the clinical implications of the MRGPI-based groups were comprehensively characterized. Gene set enrichment analysis (GSEA) found that immune-related pathways, including inflammatory and adaptive immune response, and activated eicosanoid metabolic pathways were enriched in the MRGPI-high group. Besides, genes constituting the MRGPI was primarily expressed by monocytes and macrophages at single-cell scope and was associated with the alternative activation of macrophages. Moreover, correlation analysis and receiver operating characteristic (ROC) curves revealed the relevance between the MRGPI with the expression of immune checkpoints and T cell dysfunction. Thus, the responsiveness of samples in the MRGPI-high group to immune checkpoint inhibitors (ICI) was detected by algorithms, including Tumor Immune Dysfunction and Exclusion (TIDE) and Submap. In contrast, the MRGPI-low group had favorable outcome, was less immune active and insensitive to ICI. Together, we have developed a promising biomarker to classify the prognosis, metabolic and immune features for GBM, and provide references for facilitating the personalized application of ICI in GBM. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513135/ /pubmed/36177003 http://dx.doi.org/10.3389/fimmu.2022.941556 Text en Copyright © 2022 Ji, Liu, Wang, Sun, Wang, Liu, Hu and You https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ji, Hang
Liu, Zhihui
Wang, Fang
Sun, Haogeng
Wang, Nan
Liu, Yi
Hu, Shaoshan
You, Chao
Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title_full Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title_fullStr Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title_full_unstemmed Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title_short Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
title_sort novel macrophage-related gene prognostic index for glioblastoma associated with m2 macrophages and t cell dysfunction
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513135/
https://www.ncbi.nlm.nih.gov/pubmed/36177003
http://dx.doi.org/10.3389/fimmu.2022.941556
work_keys_str_mv AT jihang novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT liuzhihui novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT wangfang novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT sunhaogeng novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT wangnan novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT liuyi novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT hushaoshan novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction
AT youchao novelmacrophagerelatedgeneprognosticindexforglioblastomaassociatedwithm2macrophagesandtcelldysfunction